Expression Of FOXC2 In Serum Of Patients With Gynecological Malignancies

Objective: The purpose of this research was to explore the expression of FOXC2 protein in serum with gynecological malignancies patients, and to check if FOXC2 could be regard as a new tumor marker for early diagnosis of gynecological malignancies. Through the research, a new way for differential diagnosis and tracing the source of tumor tissue could be set up, and the theoretical basis for the pathogenesis of gynecological malignant could be provided.Methods: 30 patients with gynecological malignancies who were diagnosed by surgery and pathology were devided as follows: 10 ovary (epithelial) cancer, 10 cervical carcinoma, 10 endometrial carcinoma. All of the cases had not received any chemotherapy or radiotherapy before. And another 10 healthy female volunteers were selected as controls. The inform consents were all obtained. The serum level of FOXC2 was tested by enzyme-linked immunosorbent assay (competitive inhibition assay). Difference of FOXC2 level among the 4 groups was analyzed using independent sample t test and single factor analysis of variance q test for statistical analysis. Each group of serum samples were taken in accordance with the characteristics of different samples using `pathological stage and (or) level of grade differentiation arranged classification comparison. The serum protein content's overall trend described distribution, predicting the serum protein content on a large sample trends.Results:①The serum level of FOXC2 in patients with epithelial ovarian cancer was significantly higher than the healthy group, the difference was significant (P <0.01), but the serum level of FOXC2 in endometrial carcinoma and cervical cancer group had no significant difference comparing to the healthy female group (P> 0.05).②FOXC2 protein level in ovarian epithelial cancer was higher than in cervical carcinoma group, the difference was statistically significant (P<0.05); comparing the FOXC2 protein content between ovarian epithelial cancer and endometrial carcinoma group , there were high significant, the difference was statistically significant (P<0.01); there was no significant difference between the endometrial carcinoma and cervical carcinoma groups (P> 0.05).③In the ovarian epithelial cancer serum samples, according to the different degree of differentiation grade , arranged the serum of ovarian malignances group from poorly differentiated sample to well- differentiated sample, poorly differentiated in 5 cases, 2 cases of poorly- moderately differentiated and moderately differentiated in 2 cases, 1 case was well-differentiated, we found in serum of different types of differentiation, As the degree of differentiation becoming lower the expression of FOXC2 protein in the escalating trend, the percentage of enzyme products combined rate was gradual reduction (competitive inhibition method), that means the A. value was lowing.④arranged the endometrial carcinoma serum samples based on different pathological stage by downingⅣB (1case)-ⅠC(1case) -ⅠB(6 cases) -ⅠA(2cases), we found that even in the same period, the binding rate had higher variability; according to degree of differentiation grade from poorly differentiated to well differentiation : poorly differentiated (2 cases)- moderately differentiated (5 cases)-well differentiated (3 cases), We found that the expression of FOXC2 protein in serum was gradual downward trend with the degree of differentiation grade becoming higher. that is, the percentage binding of enzyme products gradually increased (competitive inhibition method), the absorbance of A. becoming higher.⑤collected cervical carcinoma group were 8 cases of pathological type of squamous cell carcinoma, 1 case of adenosquamous carcinoma and adenocarcinoma in 1 case, according to clinical stage differences in the serum samples from theⅡB (3 cases)-ⅡA~ⅡB(1 case)-ⅡA(1 case )-ⅠB (4 cases) - in situ (1 case) arrangement drawings, we found that enzyme combined percentage rate is variable. According to the degree of differentiation grade, poorly differentiated (2 cases)-moderately differentiated (6 cases)-well differentiated (2 cases) order, found that the expression of FOXC2 protein in serum was a steady downward trend following to the degree of differentiation grade increased, that the percentage of enzyme binding products gradually increased (competitive inhibition method), absorbance of A. increased.Conclusion: 1). FOXC2 protein in patients with epithelial ovarian cancer were significantly higher than healthy people. the endometrial carcinoma group and cervical carcinoma group comparing the healthy female group had non- disparation of statistics. 2). The content of FOXC2 protein in epithelial ovarian cancer, endometrial carcinoma and cervical carcinoma in serum tended to increase accompanying with the degree of differentiation grade decreased. 3). FOXC2 protein in serum of patients with epithelial ovarian cancer were significantly higher than endometrial carcinoma and cervical carcinoma groups.